Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnetic device shows promise for chronic foot pain

NCT ID NCT05922618

Symptom relief Sponsor: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a device that delivers pulsed electromagnetic fields (I-ONE) could help people with complex regional pain syndrome (CRPS) of the foot or ankle. Twenty-eight participants received the device therapy plus standard rehabilitation. Researchers measured pain, swelling, and joint function to see if the combination improved recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pulsed electromagnetic field therapy (I-ONE device)
What this could lead to
If successful, this approach could offer a non-drug option to ease pain and improve function in people with complex regional pain syndrome of the foot or ankle.
What could go wrong
This is a small, completed trial with only 28 participants. Results may not apply to everyone, and the device is not a cure—it aims to manage symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

28 people

The number who actually took part.

Started

Aug 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of type I CRPS according to the Budapest criteria (table 1) * Type I CRPS involving the ankle or foot * Onset of CRPS type I up to a maximum of 3 years after the symptomatic event * Pain on visual analog scale (VAS) scale quantified as intensity at least ≥ 5 at recruitment * Pharmacological treatment with first infusion cycle of neridronate Exclusion Criteria: * Neurological pathologies (stroke, degenerative, traumatic pathologies) * Local neurological impairment (type II CRPS), confirmed by a conduction test or similar * Cardiac pacemaker, treatment site malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ankle disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arthralgia complex regional pain syndrome complex regional pain syndrome type 1 Foot Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ankle disease Complex regional pain syndromes Foot diseases Pain, joint

Contacts and locations

Locations

  • Angela Notarnicola

    Bari, 70124, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.